Compliance Frameworks in Pharmaceutical IT: A Comparative Analysis

Pharmaceutical IT operations are subject to a complex web of regulatory and industry compliance frameworks aimed at protecting patient data, ensuring data integrity, and safeguarding privacy. In the United States, pharma companies must navigate laws like HIPAA and FDA GxP regulations, as well as industry standards such as HITRUST. Global operations may introduce additional requirements – for example, France’s HDS certification for health data hosting and the Netherlands’ NEN 7510 standard for healthcare information security. This report provides an educational comparison of several key frameworks: ASIP Santé HDS (France), EPCS (Electronic Prescriptions for Controlled Substances, US), FDA GxP / 21 CFR Part 11 (US), HIPAA (US), HITRUST CSF, MARS-E (US), and NEN 7510 (Netherlands). We focus on their relevance to U.S.-based pharmaceutical IT, comparing their scope, data protection and privacy requirements, auditability, cloud applicability, enforcement, and typical use cases in pharma/health tech. Key similarities and differences are highlighted in tables and narrative to help IT professionals understand how these frameworks align and where they diverge.

ASIP Santé HDS – French Health Data Hosting Certification (France)

What it is: Hébergement de Données de Santé (HDS) is a French certification requirement that applies when an entity provides a specified hosting service for qualifying personal health data, for the patient or the person or organization that originated or collected the data. Handling French patient data alone does not automatically establish HDS applicability (^[1]). Mandated by the French Public Health Code, HDS ensures that hosting providers implement stringent security and privacy controls (^[2]) (^[3]). Originally overseen by the French eHealth agency (ASIP Santé), since 2018 the certification is issued by accredited bodies under standards integrated with ISO 27001 (^[4]). HDS certification covers strong access controls, encryption, backup reliability, and contractual obligations to protect patient data (^[5]). 2024-2026 Major Update: A significant revision to HDS (v2.0) was published on May 16, 2024. New applicants have been assessed against the revised framework since November 16, 2024. The new framework streamlines requirements from 44 to 31 (organized under four chapters) while adding stronger data sovereignty provisions (^[6]). Key changes include: mandatory EEA data localization (health data must be physically hosted exclusively within the European Economic Area), requirements to disclose any third-country access risks, and public mapping of any data transfers outside the EEA (^[7]). The transition for previously certified providers ended on May 16, 2026. All valid HDS certificates now attest exclusively to conformity with the v2 framework; certificates issued under v1.1 are no longer valid. Google Cloud achieved HDS v2.0 certification in 2025, becoming one of the first hyperscale cloud providers certified on the new framework (^[8]). Relevance to US Pharma: A U.S. pharma company should assess whether it or its provider performs a specified hosting service for qualifying personal health data, for the patient or the person or organization that originated or collected the data. Where those conditions are met, the host must hold HDS certification; operating in France or handling French patient data alone does not automatically trigger that requirement (^[1]). Even major cloud vendors (Microsoft, AWS, Google) have obtained HDS so that healthcare clients – including pharma – can use their services in France (^[3]). If the statutory conditions are met, using a non-certified host can violate French law; GDPR obligations require separate analysis. The Agence du Numérique en Santé reported 411 certified HDS providers in May 2026.

EPCS – Electronic Prescriptions for Controlled Substances (US)

What it is: EPCS is a U.S. Drug Enforcement Administration (DEA) rule framework that regulates how controlled substance prescriptions can be issued and managed electronically. Introduced in 2010 (21 CFR Parts 1300, 1304, 1306, 1311), these regulations allow practitioners to write and pharmacies to dispense controlled drug prescriptions in purely electronic form (^[9]). EPCS mandates strict identity proofing for prescribers (using NIST-assurance standards), two-factor authentication for signing prescriptions, secure transmission, and tamper-resistant audit trails to prevent fraud or diversion (^[10]) (^[11]). 2025-2026 Updates: The CMS EPCS Program now fully enforces requirements for Medicare Part D prescriptions, with prescribers considered compliant if their EPCS rate is 70% or higher (^[12]). CMS finalized a policy exempting long-term care (LTC) facility prescriptions from compliance calculations until January 1, 2028. On telemedicine, the DEA extended COVID-era flexibilities allowing controlled substance prescribing via telehealth without an in-person visit through December 31, 2026 (^[13]). A January 2025 proposed rule would require EPCS for all prescriptions issued under a special telemedicine registration, along with patient identity verification via government-issued photo ID (^[14]). More than half of U.S. states now have state-level EPCS mandates in effect (^[15]). Relevance to US Pharma: While EPCS primarily concerns healthcare providers and pharmacies, it impacts pharmaceutical IT in any systems that handle e-prescriptions of controlled drugs. For example, if a pharma company provides clinical software or patient support programs involving prescription workflows, those systems must be EPCS-compliant. As of 2024, more than 16% of prescribers were still not enabled for electronic prescribing, while pharmacy adoption is stronger with only 4% remaining non-compliant (^[16]). Compliance is enforced through DEA oversight and, in Medicare's case, program penalties. Violations – such as dispensing controlled meds from non-compliant systems – risk DEA sanctions (e.g. loss of DEA registration) and other legal liabilities.

FDA GxP / 21 CFR Part 11 – Electronic Records & Signatures (US)

What it is: GxP is an umbrella term for "Good Practice" quality guidelines (e.g. Good Laboratory, Clinical, Manufacturing Practices) in FDA-regulated industries. 21 CFR Part 11 is the specific FDA regulation that sets requirements for electronic records and electronic signatures used to fulfill any FDA record-keeping requirements (^[17]) (^[18]). In effect since 1997, Part 11 allows pharma and biotech companies to use digital systems in place of paper, so long as those systems ensure data trustworthiness and integrity (^[19]). Key Part 11 controls include user access controls, secure electronic signatures linked to user identity, and record-retention controls. FDA’s current scope guidance states that it intends to exercise enforcement discretion for specified Part 11 validation, audit-trail, record-retention, and record-copying requirements; applicable predicate-rule requirements and record-integrity obligations remain enforceable. (^[20]) (^[21]). The goal is to prevent data tampering and ensure that electronic data (e.g. clinical trial data, manufacturing records) is reliable for regulatory decisions. 2025-2026 Trends: While the core Part 11 regulation remains largely unchanged (Title 21 was last amended on January 15, 2026), FDA's enforcement focus has expanded to include hybrid systems that combine manual and electronic processes, where data integrity gaps often occur (^[22]). FDA issued final Computer Software Assurance (CSA) guidance in September 2025 and superseded it with revised final guidance in February 2026. The guidance recommends a risk-based approach for computer and automated data-processing systems used in medical-device production or quality-management systems; it is not pending general pharmaceutical Part 11 guidance (^[23]). Regarding AI, FDA has not issued detailed guidance on AI in Part 11 contexts; however, the assumption is that any AI use in regulated systems is fully subject to existing compliance requirements – companies remain fully accountable for AI-generated outputs and any resulting data integrity issues (^[24]). Relevance to US Pharma: Part 11 compliance is fundamental for any U.S. pharmaceutical IT system that manages data subject to FDA oversight – from electronic batch records in manufacturing to clinical study databases. FDA inspectors routinely audit Part 11 controls during facility inspections. While Part 11 doesn't have preset fines like privacy laws, non-compliance can trigger FDA warning letters and enforcement actions, jeopardizing drug approvals or resulting in product recalls. (Data integrity violations related to Part 11 have been among the top reasons for FDA warning letters in recent years.) Part 11 also intersects with cloud computing: pharma companies may use cloud-based software for regulated data, but they remain responsible for validating those systems and ensuring vendors support necessary controls (^[25]). FDA and industry guidance now provide strategies for using cloud in GxP environments, but ultimate accountability for compliance rests with the pharma company.

HIPAA – Health Insurance Portability and Accountability Act (US)

What it is: HIPAA is a U.S. federal law (and associated regulations) establishing national standards for protecting protected health information (PHI). Two main rules under HIPAA are critical: the Privacy Rule (45 CFR Part 160 and Subparts A & E of Part 164) and the Security Rule (Subparts A & C of Part 164). The Privacy Rule governs how PHI can be used or disclosed, giving patients rights over their health data, while the Security Rule sets administrative, physical, and technical safeguards for electronic PHI. These include access controls, audit logs, data transmission security (encryption is “addressable” but essentially expected for Internet transmission), and ongoing risk assessments (^[26]) (^[27]). HIPAA applies to covered entities (healthcare providers, insurers, clearinghouses) and their business associates (vendors handling PHI on their behalf). Relevance to US Pharma: Pharmaceutical companies are not typically covered entities per se. A pharmaceutical company is subject to HIPAA only when it is a covered entity or meets the definition of a business associate—for example, by performing a defined function or service involving PHI on behalf of a covered entity or another business associate. Operating a patient-support program, conducting research, maintaining pharmacovigilance data, or possessing health information does not by itself establish HIPAA status. Even outside of formal HIPAA scope, pharma firms handling health data often adopt HIPAA-like controls as best practice. Enforcement is handled by HHS’s Office for Civil Rights (OCR) (^[28]). HIPAA violations can lead to tiered civil money penalties. HHS currently lists a range of $127 to $63,973 per violation and calendar-year caps of $25,000 to $1,919,173 for identical violations, depending on the violation category and subject to HHS's enforcement-discretion policy (^[29]). In egregious cases (e.g. intentional misuse of PHI), criminal penalties and DOJ prosecution can apply (^[27]). Healthcare breaches continue to escalate dramatically – 2024 was the worst year on record, with 742 data breaches affecting over 276 million individuals, representing 81% of the U.S. population (^[30]). The Change Healthcare ransomware attack alone compromised an estimated 190 million records. In 2025, while breach numbers declined slightly (approximately 642 breaches affecting 57 million individuals by year-end), healthcare remains the costliest sector for data breaches at $7.42 million per incident (^[31]). Major Regulatory Updates: HHS issued a proposed HIPAA Security Rule on January 6, 2025. HHS continues to identify it as a proposed rule, not a final rule. Its proposed controls include stronger encryption and multifactor-authentication requirements, but they are not current HIPAA requirements unless and until a final rule is published. (^[32])

HITRUST CSF – Unified Security Framework (Industry Standard)

What it is: HITRUST CSF (Common Security Framework) is an industry-developed certification framework widely used in the healthcare sector to manage information security compliance. Unlike the laws above, HITRUST is voluntary – it's not a law or regulation, but rather a comprehensive set of controls that harmonize requirements from HIPAA, NIST, ISO 27001, GDPR, and other standards (^[33]) (^[34]). The HITRUST Alliance (a collaboration of healthcare organizations) created the CSF to provide a "certifiable" way to demonstrate due diligence in protecting health information. The framework contains 14 control categories, 49 objectives, and 156 references, with organizations implementing 44 (e1), 182 (i1), or a tailored number of requirements depending on the assessment type (^[35]). Organizations can undergo a rigorous third-party audit to become HITRUST CSF Certified, which is valid for 2 years with an interim review (^[36]). 2025-2026 Updates: HITRUST released CSF v11.6.0 in August 2025 and v11.7.0 in December 2025. Key changes in v11.6.0 include continued requirement consolidation to reduce overlap, added CMS ARC-AMPE mapping (replacing MARS-E v2.2), and a refreshed CMMC Level 1 mapping (^[37]). As of March 31, 2026, new e1 and i1 assessments must use v11.6.0 or later. HITRUST’s 2026 Trust Report states that 99.62% of HITRUST-certified environments remained breach-free (^[38]). Relevance to US Pharma: Many pharmaceutical and life science companies pursue HITRUST certification, especially if they handle large volumes of PHI or provide services to covered entities. HITRUST certification can serve as a proxy to assure partners (e.g. hospitals, payers) that the company meets HIPAA and other security requirements. It is often requested in B2B agreements. While not mandated by law, HITRUST is considered one of the most commonly adopted frameworks in US healthcare (^[33]). It provides a structured approach to compliance that can simplify audits and risk management. Penalties: There are no government-imposed penalties for not being HITRUST certified – it's a business decision. However, lacking strong security controls could lead to HIPAA violations or data breaches, which have legal consequences. Conversely, achieving HITRUST certification can qualify an organization for certain benefits (for example, the HIPAA Safe Harbor provision in the 2021 HITECH amendment recognizes use of "recognized security practices" – HITRUST is often cited as an example – as a factor to mitigate penalties in a breach). In sum, HITRUST is a valuable framework for pharma IT to "prove" compliance and security, beyond just trusting internal policies (^[39]).

MARS-E – Minimum Acceptable Risk Standards for Exchanges (US) / ARC-AMPE

What it is: MARS-E was a set of security and privacy standards required for the health insurance exchanges established under the Affordable Care Act (ACA). When the ACA set up federal and state insurance marketplaces, it tasked HHS's Centers for Medicare & Medicaid Services (CMS) with developing protocols to protect the sensitive data those exchanges handle (^[40]). The original MARS-E incorporated controls from NIST Special Publication 800-53 (the U.S. federal information security standard) and tailored them to healthcare exchanges. It covered protection of Personally Identifiable Information, Protected Health Information, and Federal Tax Information in these systems. 2025-2026 Major Update – Transition to ARC-AMPE: CMS published a new framework called Acceptable Risk Controls for ACA, Medicaid, and Partner Entities (ARC-AMPE) Version 1.02 on April 9, 2025, which replaces MARS-E (^[41]). This represents a comprehensive modernization effort based on NIST SP 800-53 Revision 5 (upgraded from Rev 4 in MARS-E). The minimum control baseline for ARC-AMPE includes 402 controls for Administering Entities (AEs) and 308 controls for Direct Enrollment Entities (DEEs) – a significant increase from the MARS-E baseline (^[42]). CMS lists ARC-AMPE as effective March 4, 2025, with a compliance date of March 4, 2026; that compliance date has passed. The System Security and Privacy Plan (SSPP) template has also changed from Word to Excel format. Notably, HITRUST CSF v11.6.0 added CMS ARC-AMPE mapping while removing the MARS-E v2.2 mapping (^[43]). Relevance to US Pharma: MARS-E/ARC-AMPE mainly applies to state agencies and contractors operating ACA exchanges. A pharmaceutical IT team would encounter these requirements if the company provides solutions to or integrates with an exchange or a related government health program. For instance, if a pharma company builds an application that connects to state Medicaid/insurance eligibility systems (which may leverage the exchange infrastructure), compliance with ARC-AMPE controls will be required by contract. In general, pharma companies are not directly regulated by these standards, but those working in health IT should be aware of them as a federally driven security baseline for handling health insurance data. ARC-AMPE/MARS-E compliance is typically verified through security assessments and attestations to CMS; non-compliance could result in loss of the authority to connect to federal data services or jeopardize funding for a state program. In practice, ARC-AMPE alignment means meeting a level of rigor comparable to FedRAMP Moderate (since exchanges often rely on cloud services).

NEN 7510 – Information Security in Healthcare (Netherlands)

What it is: NEN 7510 is the Dutch national standard for information security management in the healthcare sector. Developed by the Netherlands Standardization Institute (NEN), it provides a framework of controls supplementary to ISO/IEC 27001 but tailored to protect patient health information in Dutch healthcare organizations (^[44]). In essence, NEN 7510 adapts the international ISO 27001/27002 security controls to the healthcare context, emphasizing patient data confidentiality, integrity, and availability. Additional Dutch-specific requirements (e.g. around privacy laws and healthcare workflows) are included. NEN 7510 is often accompanied by related standards NEN 7512 (on secure exchange of health data) and NEN 7513 (on logging access to electronic health records), which address specific aspects of healthcare data handling. 2024–2026 Updates: NEN 7510-1:2024 introduced structural changes aligned with ISO/IEC 27001:2022. The current controls component is NEN 7510-2:2024+A1:2026, a consolidated version published on March 1, 2026; it replaced NEN 7510-2:2024 (^[45]). Organizations should assess NIS2 and other legal obligations separately rather than treating a NEN 7510 edition as a substitute for those obligations. Relevance to US Pharma: For a U.S. pharmaceutical company, NEN 7510 becomes relevant if the company operates in the Netherlands or handles Dutch patient data (for example, running clinical trials in Dutch hospitals or offering a digital health service to Dutch patients). Article 3 of the Dutch Decree on electronic data processing requires healthcare providers to follow NEN 7510, NEN 7512, and NEN 7513 when using healthcare information systems (^[46]). As of 2023, all hospitals must demonstrably comply with NEN 7510. Dutch healthcare institutions may require their IT suppliers to comply with NEN 7510 as a condition of doing business. U.S. companies might seek NEN 7510 certification via accredited auditors. No direct government fines are tied to NEN 7510 itself, but failing to secure health data could violate Dutch data protection law (AVG/GDPR). Importantly, organizations demonstrating NEN 7510 compliance are already well on the road to NIS2 compliance (^[47]).

To clarify how these frameworks compare, Table 1 provides an overview of their scope, nature, and enforcement, and Table 2 summarizes their requirements for data protection, audit, and cloud use. Further discussion of specific aspects follows.

Table 1 – Scope, Applicability, and Enforcement of Compliance Frameworks

Table 2 – Key Requirements, Auditability, and Cloud Considerations

Regulatory Scope and Applicability

These frameworks differ in whether they are legally mandated or voluntary, and in the sectors they cover. U.S. pharma IT will prioritize compliance with mandatory regulations first: e.g. 21 CFR Part 11 (when applicable FDA-regulated records are involved), HIPAA (when the organization is a covered entity or business associate), and EPCS (if facilitating controlled-substance prescriptions). HDS (France) is legally relevant only when its statutory conditions are met: qualifying personal health data collected in prevention, diagnosis, care, or social or medico-social support is hosted through a specified service for the patient or for the person or organization that originated or collected it. NEN 7510 is relevant in its respective jurisdiction based on the applicable legal and contractual context. MARS-E is mandated for a specific U.S. federal context (ACA exchanges) and would matter if a pharma’s work intersects with that context (typically via contracts or data-sharing with government systems). In contrast, HITRUST is not required by law but has become an industry norm; its scope is broad (any org in healthcare) and it essentially overlays other regulations rather than introducing new ones. Table 1 shows that most of these frameworks tie back to protecting health-related data, but some (EPCS, Part 11) are more narrowly scoped to certain processes (prescriptions, FDA records) rather than all health information. (^[1])

One key distinction is between national vs. industry scope: HIPAA, Part 11, EPCS, MARS-E, and the international HDS/NEN 7510 are backed by governments or standards bodies, whereas HITRUST is a private-sector initiative. This affects how they are adopted – e.g., HITRUST adoption is driven by business requirements and risk management, not by fear of regulatory fines. By contrast, failing to comply with the government-driven frameworks can halt operations (FDA can block a non-compliant study or drug, OCR can levy fines, France can ban a non-HDS host, etc.).

Data Protection and Privacy Requirements

All the frameworks aim to protect data, but their emphasis can vary between privacy (controlling access and use of personal data) and security/integrity (preventing unauthorized change or loss of data):

• Privacy Focus: HIPAA defines and limits uses and disclosures of PHI. It permits treatment, payment, and health-care-operations uses and disclosures without an individual’s authorization; patient consent for those purposes is optional. Written authorization is generally required for uses or disclosures not otherwise permitted or required by the Privacy Rule. HDS and NEN 7510, while framed as security standards, are deeply influenced by privacy regulations (GDPR); for instance, HDS incorporates GDPR principles and NEN 7510 addresses Dutch privacy law in healthcare (^[48]). MARS-E has privacy rules restricting data usage to ACA purposes. HITRUST includes a privacy module that maps to HIPAA and GDPR requirements for organizations that choose to include it. EPCS is somewhat less about privacy (the data in a prescription is medical but the framework’s goal is to ensure the prescription is authentic, not to give patients control over it), though it inherently protects patient info by securing the prescribing process. (^[62])

• Security/Integrity Focus: All frameworks require strong access controls and audit logs. Part 11 and EPCS are heavily integrity-focused – ensuring that records (whether an FDA submission data file or a prescription record) cannot be manipulated or forged without detection (^[19]) (^[53]). HDS and NEN 7510 provide broad security controls (mirroring ISO 27001, covering everything from facility security to network security). MARS-E, based on NIST, is extremely comprehensive on security controls for confidentiality, integrity, and availability. HIPAA’s Security Rule is a bit less prescriptive than NIST or ISO, but it covers similar ground; however, HIPAA also requires consideration of physical safeguards (facility access, device and media controls) which align with those broader standards. HITRUST, being comprehensive, spans both privacy and security: an organization adopting HITRUST will by default implement encryption, access control, continuous monitoring, etc., often to a higher level than the minimum required by HIPAA or FDA. Table 2 highlights, for instance, that HDS mandates encryption and backup and EPCS mandates 2FA; for Part 11, audit trails or other controls depend on applicable predicate rules, FDA’s stated enforcement discretion, and a documented risk assessment. Each framework has specific focal requirements, but there is substantial overlap among them in terms of baseline security best practices (access control, monitoring, and so forth).

Another difference is patient rights: HIPAA (and by extension HITRUST’s privacy controls) gives individuals rights to their data, whereas frameworks like Part 11 or EPCS don’t address individual rights – they are concerned with system behavior. NEN 7510 being tied to GDPR means patients’ rights in Netherlands (e.g. right to access their medical records) are indirectly supported by the standard, but those rights come from GDPR, not NEN 7510 itself.

Auditability and Certification

Several frameworks come with formal certification or audit regimes:

• Government Audits: HIPAA is enforced through OCR audits/investigations, and FDA inspects Part 11 compliance during audits of plants or clinical sites. These are after-the-fact audits (to find non-compliance) rather than upfront certifications. Similarly, CMS can audit MARS-E compliance through required security reviews. There’s no certificate to hang on the wall for these; instead, organizations maintain evidence (policies, logs, risk assessments) to prove compliance when scrutinized.

• Third-Party Certifications: HDS (France) and NEN 7510 (NL) both involve certification by accredited third parties. In France, an entity that provides an in-scope hosting service for qualifying personal health data must obtain the HDS certificate (^[2]) (^[49]), which in practice means passing a rigorous audit (covering ISO 27001 and additional controls) and periodic renewal. NEN 7510 certification is not legally mandatory, but widely pursued; often it’s done in tandem with ISO 27001 certification. HITRUST is purely a third-party certification – a detailed audit that results in a score and certificate if passing. These certifications often reassure business partners and regulators. For instance, a French hospital knows a cloud service is safe to use if it’s HDS-certified, and a Dutch hospital may prefer vendors with NEN 7510 certification.

• Audit Trail Requirements: It’s worth noting that “auditability” is also literal. For Part 11, whether computer-generated audit trails are required depends on applicable predicate rules and FDA’s stated enforcement discretion for specified Part 11 audit-trail provisions. HIPAA requires audit controls for systems containing or using electronic PHI, but does not prescribe a single audit-log design. NEN 7513 (a companion to NEN 7510) explicitly requires logging of who accessed which patient file and when. Thus, pharma IT systems that fall under these frameworks must have technical logging capabilities – something developers and IT architects must plan for early. In contrast, HITRUST as a framework will ask “do you have audit logging enabled for critical systems?” as a control, but it’s up to the organization to implement it appropriately.

• Internal Audits and Maintenance: All frameworks expect ongoing compliance, not a one-time effort. Pharma companies must conduct regular internal audits for Part 11 (often part of quality management), periodic risk assessments for HIPAA, and annual control testing for HITRUST (interim assessment on year 1). HDS and NEN 7510 certifications typically last 2-3 years, but require surveillance audits in between. MARS-E requires continuous monitoring; exchanges must submit yearly attestation packages to CMS. So for an IT team, compliance is an operational continuous process – e.g., ensuring user access reviews happen every quarter as required, verifying that new cloud deployments follow the rules, etc.

Cloud and Infrastructure Considerations

Modern pharmaceutical IT is heavily cloud-based. Each framework has adapted (or is in process of adapting) to cloud realities:

• ASIP HDS: This one is intrinsically about cloud/hosting. It explicitly allows cloud providers to be certified. Indeed, France has used HDS to bring big cloud providers into compliance (Azure, AWS, etc. are certified hosts) (^[3]). A U.S. pharma using a cloud data center in France should assess whether the provider performs an in-scope hosting service for qualifying personal health data; if so, the provider must be HDS-certified. HDS also now has data residency requirements (EEA only) (^[48]), which for cloud means using EU regions exclusively for French health data.

• HIPAA: Initially, people were cautious about cloud for HIPAA workloads. Now it’s common, but the key is the Business Associate Agreement (BAA). All major cloud vendors sign BAAs, promising to implement HIPAA safeguards and be accountable. Pharma IT teams must choose cloud configurations that are “HIPAA-eligible” (for example, using encrypted storage, not using services that aren’t covered by the provider’s BAA). There have been cases where cloud misconfigurations led to HIPAA breaches (e.g., an open S3 bucket exposing PHI). So compliance involves both the cloud provider’s assurances and the client’s correct use of the cloud. In regulated trials (Part 11) on cloud, similar principles apply: choose cloud services that support needed compliance (e.g., AWS offering Audit Manager for Part 11 controls (^[63])).

• FDA Part 11 (GxP): FDA has not issued cloud-specific regulations, but industry practice has evolved. Pharma companies now often use SaaS for things like electronic Trial Master Files or pharmacovigilance databases. The company must perform vendor qualification (making sure the SaaS provider follows good development and validation practices) and ensure they can get audit trail data and have data portability. The FDA guidance from 2003 remains available and describes enforcement discretion for specified Part 11 validation, audit-trail, record-retention, and record-copying provisions; it does not remove applicable predicate-rule obligations. With cloud, companies typically negotiate quality agreements with vendors. In short, cloud is acceptable for Part 11 as long as you can demonstrate control over compliance features of that cloud system. Notably, many vendors in life sciences now advertise Part 11 compliance, which helps.

• HITRUST: The framework fully embraces cloud and even remote workplaces – it has controls for cloud security configuration and mappings to cloud standards. A HITRUST assessment will incorporate cloud-specific issues (for example, requiring encryption keys management, cloud network segmentation, etc., if in scope). Moreover, cloud providers like Microsoft and Amazon have obtained HITRUST certification for certain services, meaning a pharma company can inherit those controls and reduce their own assessment burden.

• MARS-E: MARS-E’s alignment with NIST 800-53 means it naturally dovetails with federal cloud standards (FedRAMP). Many state exchanges run on FedRAMP-certified cloud environments. Pharma IT rarely needs FedRAMP unless working on government contracts, but if it does, knowing MARS-E/NIST is key. For instance, if a pharma company builds a data system for a federal health agency, it might need to meet similar requirements.

• NEN 7510: As mentioned, Dutch health data can be in cloud, but typically a European cloud. U.S. companies have to be mindful of Schrems II (EU’s ruling on data transfers) – using an EU data center is one solution, but being NEN 7510 compliant also shows you’ve taken appropriate security measures, which is part of GDPR’s requirements (GDPR Art. 32 requires security appropriate to risk). Some Dutch healthcare providers might stipulate that cloud services must not only be in EU but also have ISO 27001 and preferably NEN 7510 certification. This can influence which vendors a pharma can choose for a project.

In summary, none of these frameworks forbid cloud outright, but they demand due diligence and often additional controls in cloud deployments. The era of having to keep data on-premise for compliance is largely over; now the focus is on configuring cloud services securely and meeting the documentation requirements.

Penalties for Non-Compliance

Penalties and consequences vary widely:

• Financial penalties and legal risk: HIPAA provides for civil money penalties and, in some cases, criminal penalties. HHS currently lists civil-penalty ranges of $127–$63,973 per violation and calendar-year caps of $25,000–$1,919,173 for identical violations, depending on category and subject to enforcement discretion (^[29]). A pharmaceutical company acting as a business associate could face enforcement action if it violates applicable HIPAA requirements. For example, if a patient-support-program database is breached because required Security Rule safeguards were not in place, OCR could impose penalties or require corrective action. HDS and NEN 7510 don’t have dedicated fine schedules, but non-compliance can trigger GDPR fines (which can be up to 4% of global turnover) if a data breach or unlawful processing happens. In France, hosting health data without HDS certification is essentially illegal – authorities could order cessation of service and potentially levy fines under general health code violations. EPCS violations (like a pharmacy filling invalid e-prescriptions) can lead to DEA enforcement; while DEA typically focuses on revoking controlled substance licenses, there can be fines under the Controlled Substances Act. MARS-E non-compliance could mean a state loses federal support; also, a data breach in a health exchange could bring multi-agency investigations (FTC, state attorneys general, etc.). Part 11 non-compliance hits companies in different ways: if FDA finds issues, they might require expensive remedial actions or delay a product approval (which has huge financial implications even if not “fines”). In extreme cases, companies like a contract research organization could face contractual liabilities or lawsuits if their data integrity issues invalidate a trial.

• Operational impact: Beyond fines, the bigger risk in pharma is often operational. Losing FDA trust (Part 11) can stop a clinical trial or force a plant shutdown. For an HDS host, loss of certification can prevent it from providing hosting services that fall within the HDS legal framework; it does not mean that every form of patient-data storage in France is prohibited. If a pharma isn't HITRUST certified, it might simply be locked out of certain client pools (e.g., a hospital might choose a competitor's solution because they have HITRUST). HITRUST’s 2026 Trust Report states that 99.62% of HITRUST-certified environments remained breach-free (^[38]). Similarly, failing to comply with EPCS means your e-prescribing feature can't be used – and with e-prescribing now nearly universal (94% of all U.S. prescriptions were electronic by 2021, with even higher rates today), that's not viable. (^[1])

• Reputation and trust: In an industry handling sensitive health data, public trust is crucial. A breach of PHI under HIPAA becomes public (HHS posts breaches on a public portal). FDA warning letters are public too. These can damage a pharma company’s reputation for safeguarding data. Achieving certifications like HITRUST, HDS, or NEN 7510 conversely can be a selling point, signaling a commitment to security and compliance.

• Use of Safe Harbors: There are emerging trends where demonstrating compliance can lessen penalties. For instance, the 2021 amendment to HITECH (in the U.S.) says HHS OCR should consider whether an entity had “recognized security practices” (like NIST CSF or HITRUST) in place for the prior 12 months when deciding penalties. That means if a pharma company has robust HITRUST/NIST-based security and still suffers a breach, it might get leniency (^[33]). Such incentives further encourage voluntary adoption of strong frameworks even when not strictly required by law.

Use Cases and Sector Applicability

Finally, each framework has its niche in the pharma/health tech environment, though overlaps exist:

• ASIP Santé HDS: Use case – A U.S. pharma launching a telehealth platform in France should assess whether it or its provider performs one of the specified hosting services for qualifying personal health data, on behalf of the patient or the person or organization that originated or collected the data. If so, the host must be HDS-certified. Likewise, transferring clinical-trial data to France for analysis does not by itself establish HDS applicability; the nature of the data, service, and parties must be assessed. (^[1])

• EPCS: Use case – A pharmaceutical company might not prescribe medications, but suppose the company develops a mobile app for pain management that allows physicians to e-prescribe the company’s controlled pain drug. The app’s e-prescription module must follow EPCS. Or a pharma might partner with pharmacies for a patient program; any electronic Rx workflows in that partnership fall under EPCS. In health IT, EPCS knowledge is crucial for EHR vendors, pharmacy IT systems, and e-prescribing service providers – pharma IT intersects when providing solutions to those stakeholders.

• FDA Part 11 (GxP): Use cases are abundant: electronic lab notebooks in R&D, LIMS (lab information systems) capturing assay data, clinical data management systems capturing trial results, electronic submission gateways, digital QA systems for manufacturing, etc. Any software that deals with data which eventually goes to the FDA or supports a GMP/GLP process must be Part 11 compliant. For example, if a pharma uses an AI tool to analyze clinical data and that data might support a filing, the tool should have Part 11 controls for traceability of data and models. Part 11 is truly pervasive in pharma IT – even Excel spreadsheets can fall under it if used for certain tracking (hence companies validate and control those too!).

• HIPAA: Use cases – A pharma support center, pharmacovigilance program, clinical trial, or health app is not subject to HIPAA merely because it handles health information. HIPAA may apply if the pharmaceutical company operates as a covered entity or performs a defined function or service involving PHI on behalf of a covered entity or business associate. Acquired or operated provider, health-plan, pharmacy, or clearinghouse operations may meet the covered-entity definition when the regulatory criteria are met. Research and hospital-data arrangements require case-specific analysis of HIPAA status and any applicable authorization, waiver, or other legal basis.

• HITRUST: Use cases – Commonly pursued by pharmaceutical service providers (e.g., a company offering a cloud platform for clinical trials or a data analytics service for hospitals). If those services involve PHI, being HITRUST certified can attract business. Pharma companies themselves sometimes get corporate HITRUST certification if they handle a lot of health data; for example, a pharma’s IT division might get certified to streamline answering security questionnaires from customers (hospitals will accept “we’re HITRUST certified” as evidence of good security). Also, if a pharma is part of a larger health network or accountable care programs, HITRUST can demonstrate their part of the network meets security expectations. Another scenario: a pharma’s patient-facing software (say a disease management app) could be developed to HITRUST standards to ensure both HIPAA and general cybersecurity are covered.

• MARS-E: Use case – This is niche for pharma, but consider a pharma working on a value-based contracting platform that needs to verify patient insurance or subsidy eligibility through an ACA exchange’s API – that system might need to implement MARS-E controls because it touches the exchange data. Or, a pharma partners with a state Medicaid agency on a population health initiative; if they handle data from the state’s systems, they may need to sign agreements to follow MARS-E or NIST security controls. In essence, whenever dealing with government health data infrastructure, be prepared to meet something like MARS-E. It’s more likely relevant to IT consulting firms and Medicaid solution vendors than to a pharma manufacturing drugs, but as pharma companies diversify into health IT solutions, this could arise.

• NEN 7510: Use case – Similar to HDS: whenever a U.S. pharma deals with Dutch patient data or systems. For example, if a pharma runs a patient registry in the Netherlands, local regulations would expect NEN 7510-level security. If they outsource IT to a Dutch company, that company will likely be NEN 7510 certified and will require the pharma to follow certain rules too. For global companies, aligning corporate security with standards like ISO 27001 means they are largely meeting NEN 7510 already, with a few tweaks for Dutch specifics.

U.S. pharmaceutical IT professionals must navigate a landscape of overlapping compliance frameworks to ensure both regulatory compliance and robust data protection. Domestic requirements such as FDA’s Part 11 can govern research and manufacturing records, while HIPAA governs pharmaceutical operations only when the organization is a covered entity or business associate. Layered atop these are specialized frameworks – EPCS securing the prescription workflow, HITRUST providing a holistic security benchmark, and MARS-E guarding government health data – which may apply based on specific business activities. For globally operating companies, France’s HDS applies only where its statutory conditions for qualifying personal-health-data hosting are met, while NEN 7510’s relevance depends on the applicable Dutch legal and contractual context. (^[1])

Despite their different origins, these frameworks share common goals and controls. Implementing one often helps with others (for instance, a strong ISO 27001/HITRUST-based security program will largely fulfill HIPAA and Part 11 requirements, with some procedural additions). Smart organizations therefore take a unified approach – mapping controls across frameworks and avoiding siloed compliance efforts. The use of clear comparison matrices (like those in this report) can aid in identifying where a single solution (say, an audit trail system or an encryption standard) can satisfy multiple obligations. Conversely, the differences highlighted – such as unique certification needs or specific legal penalties – underscore that compliance cannot be one-size-fits-all; each framework has “must-do” items that require attention.

In practice, achieving compliance is not just about avoiding penalties, but also about enabling business opportunities (e.g., cloud adoption, partnerships) and maintaining trust. A pharma IT department that stays informed on frameworks from HIPAA to HDS to HITRUST positions itself to support the company’s innovation (like deploying cloud-based digital health tools) in a secure and lawful manner. As regulations evolve (for example, new FDA data integrity guidance, or updates to international standards), continuing education and adaptation will be key. This comparative analysis serves as a foundation, and IT professionals should consult the latest authoritative sources – FDA guidances, HHS/OCR publications, NIST and international standards – to stay updated. By understanding and integrating these compliance frameworks, pharma companies can confidently leverage technology in delivering healthcare breakthroughs, while safeguarding the data and privacy of patients and consumers worldwide.